Keyword: Edwards Lifesciences
A study of 100 physicians who received payments from device makers declared their conflict of interest in journal articles only 37% of the time.
The agreement sees Boston Scientific buy $90 million of Millipede stock and gain the right to acquire the rest of the business for up to $450 million.
The takeover gives Edwards control of a technology to repair the hearts of patients with the degenerative form of mitral valve disease.
Medtronic has posted a look at data on the first 50 patients treated with its transcatheter mitral valve replacement (TMVR) system.
Edwards Lifesciences has earned FDA clearance for its blood flow monitoring platform.
Following a U.K. court's mixed decision, a German court found Edwards infringed two Boston Scientific patents, while Boston Sci violated one Edwards patent.
After months of patent squabbling between Boston Scientific and Edwards, a U.K. court has deemed one of Boston Sci’s heart valve patents invalid.
Edwards Lifesciences has penned a deal to buy Valtech Cardio for up to $690 million, less than the heart valve company looked set to be acquired for last year.
Edwards Lifesciences has received a CE mark for its hypotension indicator, which alerts healthcare clinicians to the potential of abnormally low blood pressure in surgical and critical care patients before such an event occurs.